Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC-HD: SD-809 ER in Huntington's Chorea
NCT01897896Phase 3Completed
- Sponsor
- Auspex Pharmaceuticals
- Start
- Nov 2013
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label trial of deutetrabenazine in Huntington disease (HD) (2 cohorts), sponsored by Auspex Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events. Started Nov 2013; status: completed.
02
Drugs
deutetrabenazine
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NCT01897896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01897896.